Proudfoot Owen, Pouniotis Dodie, Sheng Kuo-Ching, Loveland Bruce E, Pietersz Geoffrey A
Bio-Organic and Medicinal Chemistry Laboratory, Burnet Institute at Austin, Studley Rd, Heidelberg, 3084, Victoria, Australia.
Expert Rev Vaccines. 2007 Aug;6(4):617-33. doi: 10.1586/14760584.6.4.617.
There has been a surge of interest in the use of dendritic cell (DC) vaccination as cellular immunotherapy for numerous cancers. Despite some encouraging results, this therapeutic modality is far from being considered as a therapy for cancer. This review will first discuss preclinical DC vaccination in murine models of cancer, with an emphasis on comparative studies investigating different methods of antigen priming. We will then comment on the various murine DC subsets and how these relate to human DC preparations used for clinical studies. Finally, the methodology used to generate human DCs and some recent clinical trials in several cancers are reviewed.
作为多种癌症的细胞免疫疗法，树突状细胞（DC）疫苗接种的应用引发了人们极大的兴趣。尽管取得了一些令人鼓舞的成果，但这种治疗方式远未被视为一种癌症疗法。本综述将首先讨论癌症小鼠模型中的临床前DC疫苗接种，重点是研究不同抗原启动方法的比较研究。然后，我们将评论各种小鼠DC亚群以及它们与用于临床研究的人类DC制剂的关系。最后，回顾了用于生成人类DC的方法以及最近在几种癌症中的一些临床试验。
